Bill Sibold, Madrigal Pharmaceuticals

Being a Life Sciences Leader ›

31:00 | Apr 29th

Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his...Show More